Moderna ( MRNA) was the best-performing stock in the S&P 500 as Barron's called it "too cheap" and named the biotech firm as ...

Moderna is a contrarian play for 2025, despite a rough 2024 as one of the worst-performing Nasdaq-100 stocks. Click here to ...

Despite being a pioneer in developing one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have ...

Shares of Moderna Inc. MRNA shed 1.87% to $39.38 Monday, on what proved to be an all-around grim trading session for the ...

Moderna Inc (MRNA) stock saw a decline, ending the day at $40.13 which represents a decrease of $-0.30 or -0.74% from the prior close of $40.43. The stock opened at $40.35 and touched a low of $39.79 ...

Moderna's (NASDAQ: MRNA) wild success in the COVID-19 vaccine market has worn off. Despite what it seems, though, Moderna has ...

BTIG raised the firm’s price target on Personalis (PSNL ... was removed from the index. Year to date, Moderna stock has plunged over 60%, with a 52-week low-high of $35.8-$170.47, as per ...

Moderna has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. See why MRNA stock is ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 10.82% ...

GSK Plc GSK also filed a lawsuit alleging that Moderna's mRNA vaccines infringe on patents it developed. Price Action: MRNA stock is down 1.04% at $41.40 at the last check on Monday.

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) saw unusually large options trading on Friday. Stock investors acquired 127,231 put options on the stock. This represents an increase of 86% compared to ...

Shares of Moderna Inc. MRNA slid 0.74% to $40.13 Friday, on what proved to be an all-around poor trading session for the ...